Seeking Alpha

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over ...

MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences (SGHT), Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology ...
Nasdaq

Sight Sciences Announces Cost Savings Findings from TearCare® System Budget Impact Analysis for Dry Eye Disease Treatment

Sight Sciences' analysis shows TearCare can save health plans $36.87 PMPY over traditional dry eye treatments in the U.S. Results from a Budget Impact Analysis indicate that a 20% increase in market ...
Healio

Single TearCare treatment improves visual function, quality of life in dry eye disease

Please provide your email address to receive an email when new articles are posted on . More than half of participants experienced improvement in reading speed after one treatment with TearCare.
Morningstar

Azura Ophthalmics Corporate Update: AZR-MD-001 NDA Submission Expected in 2H 2026

—AZR-MD-001 is a Potential First-in-Class Therapy Targeting Meibomian Gland Dysfunction (MGD), the Root Cause of Dry Eye Disease (DED) and Contact Lens Discomfort (CLD)— Azura Ophthalmics Ltd., a ...
Women's Health

Why You Have Dry Eyes—And How To Treat Them

Add this to the list of unfair realities: Some women are at higher risk for dry eye than men, thanks to hormonal changes. "Estrogen and androgen levels play a key role in regulating the function of ...